A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases
Frontiers in Oncology · 28.05.2026 · 16
DOI: 10.3389/fonc.2026.1845249 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Oncology, online erschienen am 28.05.2026. Verfasst von Xueping Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prevention and Treatment Institute of Chengdu, Department of Oncology, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Af…. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
L-arginine may enhance radiotherapy efficacy through nitric oxide (NO)-mediated glycolysis inhibition; however, its real-time metabolic effects in brain metastases remain undefined. This proof-of-concept study aimed to characterize, for the first time in vivo , the rapid pharmacodynamic profile of intravenous L-arginine on lactate metabolism in brain metastases and generate hypotheses for future trials.
Methods
Twenty patients with solid tumor brain metastases were randomized 1:1:1:1 to receive normal saline or 10 g, 20 g, or 30 g intravenous L-arginine. Serial magnetic resonance spectroscopy (MRS) was performed at baseline and multiple post-infusion timepoints (approximately 19–36 minutes) to quantify lactate dynamics. The primary endpoint was lactate reduction at T3 (approximately 30 minutes).
Results
All patients completed the study. The pooled L-arginine group showed significantly greater lactate reduction at T3 compared with controls (median ΔLac_T3: −1.09 vs. 0.00, p = 0.0012). Lactate reduction was most prominent and consistent in the 30 g group, with a peak reduction of 63.5% at 30 minutes (ρ = −0.753, p < 0.001). No treatment-related adverse events were observed up to 24 hours post-infusion.
Conclusion
This proof-of-concept study demonstrates that intravenous L-arginine rapidly and safely suppresses lactate metabolism in brain metastases, with a peak effect at approximately 30 minutes. The 30 g dose yielded the most robust metabolic suppression within the 10–30 g range. The “30 g L-arginine followed by radiotherapy within 30 minutes” regimen is proposed as a priority candidate for validation in future phase II trials. Clinical benefits require further confirmation in larger randomized controlled trials. Clinical Trial Registration https://www.chictr.org.cn/ , identifier ChiCTR2400080841.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Prevention and Treatment Institute of Chengdu, Department of Oncology, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional…
- Department of Medical Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
- Geriatric Diseases Institute of Chengdu, Department of Orthopedics, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Me…
Zitieren
APA
Liu, X., Du, G., Mu, N., & He, L. (2026). A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1845249
Vancouver
Liu X, Du G, Mu N, He L. A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1845249
BibTeX
@article{Liu2026,
author = {Liu, Xueping and Du, Guobo and Mu, Nai and He, Lang},
title = {A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1845249}
}
EUVIMED